Sandra Garces
Overview
Explore the profile of Sandra Garces including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shubow S, Gunsior M, Rosenberg A, Wang Y, Altepeter T, Guinn D, et al.
AAPS J
. 2025 Mar;
27(2):62.
PMID: 40087239
Therapeutic drug monitoring (TDM) for dose modification of biologics has the potential to improve patient outcomes. The US Food and Drug Administration (FDA) and the American Association of Pharmaceutical Scientists...
2.
Garces S, Karis E, Merrill J, Askanase A, Kalunian K, Mo M, et al.
Lupus Sci Med
. 2023 Jul;
10(2).
PMID: 37491104
SLE is a complex autoimmune disease with considerable unmet need. Numerous clinical trials designed to investigate novel therapies are actively enrolling patients straining limited resources and creating inefficiencies that increase...
3.
Connelly K, Eades L, Koelmeyer R, Ayton D, Golder V, Kandane-Rathnayake R, et al.
Nat Rev Rheumatol
. 2023 Jul;
19(9):592-602.
PMID: 37433880
Systemic lupus erythematosus (SLE) is a disease of high unmet therapeutic need. The challenge of accurately measuring clinically meaningful responses to treatment has hindered progress towards positive outcomes in SLE...
4.
Martinez J, Hindiyeh N, Anglin G, Kalidas K, Hodsdon M, Kielbasa W, et al.
Cephalalgia
. 2020 Apr;
40(9):978-989.
PMID: 32340471
Background: This analysis characterizes the immunogenicity profile of galcanezumab, a humanized monoclonal antibody that selectively binds calcitonin gene-related peptide and inhibits its activity, in phase 3 migraine trials. Methods: Immunogenicity...
5.
Reich K, Jackson K, Ball S, Garces S, Kerr L, Chua L, et al.
J Invest Dermatol
. 2018 May;
138(10):2168-2173.
PMID: 29751001
Ixekizumab, a high-affinity monoclonal antibody that selectively targets IL-17A, is efficacious for moderate to severe plaque psoriasis. We examined relationships between serum ixekizumab concentrations, treatment-emergent anti-drug antibodies (TE-ADAs), and efficacy...
6.
Garces S, Demengeot J
Curr Probl Dermatol
. 2017 Nov;
53:37-48.
PMID: 29131036
Virtually all therapeutic proteins (biologics) elicit an immune response with the consequent production of anti-drug antibodies (ADA). The majority of ADA to therapeutic monoclonal antibodies (mAbs) are directed against the...
7.
Deehan M, Garces S, Kramer D, Baker M, Rat D, Roettger Y, et al.
Autoimmun Rev
. 2015 Mar;
14(7):569-74.
PMID: 25742758
All protein drugs (biologicals) have an immunogenic potential and we are armed with multiple guidelines, regulatory documents and white papers to assist us in assessing the level of risk for...
8.
Fonseca J, Goncalves J, Araujo F, Cordeiro I, Teixeira F, Canhao H, et al.
Acta Reumatol Port
. 2014 May;
39(1):60-71.
PMID: 24811463
Biotechnological drugs have become a fundamental resource for the treatment of rheumatic patients. Patent expiry of some of these drugs created the opportunity for biopharmaceutical manufacturers to develop biosimilar drugs...
9.
Garces S, Antunes M, Benito-Garcia E, da Silva J, Aarden L, Demengeot J
Ann Rheum Dis
. 2013 May;
73(6):1138-43.
PMID: 23666932
Introduction: Clinical remission is today the treatment goal for rheumatoid arthritis (RA), which requires fast and assertive therapeutic decisions for a tight control of disease activity. Few objective parameters are...
10.
Garces S, Demengeot J, Benito-Garcia E
Ann Rheum Dis
. 2012 Dec;
72(12):1947-55.
PMID: 23223420
Background: Immunogenicity of aTNFs is one of the mechanisms behind treatment failure. Objective: To assess the effect of anti-drug antibodies (ADA) on drug response to infliximab, adalimumab and etanercept, and...